FDA Extends Parallel Review Program ‘Indefinitely’

The program, which allows select manufacturers to have their products reviewed simultaneously for FDA approval and Medicare coverage, has been in the pilot stage since 2011. Now it is formally in full implementation mode and the agencies are looking for more manufacturers to participate.

More from Policy & Regulation

More from Medtech Insight